Omega Stock Analysis


USD 7.05  0.06  0.86%   

The current price rise of Omega Therapeutics may encourage investors to take a closer look at the company as it is trading at a share price of 7.05 on 69,533 in trading volume. The company directors and management may have good odds in positioning the company resources to exploit market volatility in January. The stock standard deviation of daily returns for 90 days investing horizon is currently 5.74. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Omega Therapeutics partners.
Please check Your Equity Center.
The Omega Therapeutics stock analysis report makes it easy to digest most publicly released information about Omega Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Omega Stock analysis module also helps to analyze the Omega Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Omega Stock Analysis Notes

About 89.0% of the company shares are owned by institutional investors. The book value of Omega Therapeutics was now reported as 2.79. The company recorded a loss per share of 2.26. Omega Therapeutics had not issued any dividends in recent years. Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people. To find out more about Omega Therapeutics contact Mahesh Karande at 617 949 4360 or learn more at

Omega Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Omega Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Omega Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Omega Therapeutics is way too risky over 90 days horizon
Omega Therapeutics appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 144 K. Net Loss for the year was (68.28 M) with loss before overhead, payroll, taxes, and interest of (47.72 M).
Omega Therapeutics currently holds about 173.66 M in cash with (57.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.63.
Over 89.0% of the company shares are owned by institutional investors

Omega Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Omega Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Omega Therapeutics backward and forwards among themselves. Omega Therapeutics' institutional investor refers to the entity that pools money to purchase Omega Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Wells Fargo CompanyCommon Shares1181000
Wells Fargo CompanyCommon Shares51.00.0
Wells Fargo CompanyCommon Shares14.3 K89 K
Wells Fargo CompanyCommon Shares13.2 K150 K
Wells Fargo CompanyCommon Shares41.01000
Wade G W IncCommon Shares10 K54 K
Wade G W IncCommon Shares10 K38 K
Note, although Omega Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Omega Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 335.86 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Omega Therapeutics's market, we take the total number of its shares issued and multiply it by Omega Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (0.2796) % which means that it has lost $0.2796 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.5239) %, meaning that it created substantial loss on money invested by shareholders. Omega Therapeutics management efficiency ratios could be used to measure how well omega therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 4th of December, Omega Therapeutics holds the Coefficient Of Variation of 691.5, risk adjusted performance of 0.2208, and Semi Deviation of 4.4. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Omega Therapeutics, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Omega Therapeutics, which can be compared to its competitors. Please check Omega Therapeutics standard deviation, value at risk, kurtosis, as well as the relationship between the jensen alpha and semi variance to decide if Omega Therapeutics is priced some-what accurately, providing market reflects its current price of 7.05 per share. Given that Omega Therapeutics has jensen alpha of 0.7561, we recommend you to check out Omega Therapeutics's recent market performance to make sure the company can sustain itself at a future point.

Omega Therapeutics Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Omega Therapeutics price series with the more recent values given greater weights.

Omega Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Omega Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Omega Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Omega Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Karande Mahesh over a month ago via Macroaxis 
Acquisition by Karande Mahesh of 170000 shares of Omega Therapeutics subject to Rule 16b-3
Young Richard A over two months ago via Macroaxis 
Sale by Young Richard A of 10000 shares of Omega Therapeutics
Boehm Rainer J over three months ago via Macroaxis 
Acquisition by Boehm Rainer J of 36713 shares of Omega Therapeutics subject to Rule 16b-3
Levy Elliott M over three months ago via Macroaxis 
Acquisition by Levy Elliott M of 18118 shares of Omega Therapeutics subject to Rule 16b-3
Mcmanus Kevin over six months ago via Macroaxis 
Acquisition by Mcmanus Kevin of 125000 shares of Omega Therapeutics subject to Rule 16b-3
Karande Mahesh over six months ago via Macroaxis 
Acquisition by Karande Mahesh of 340000 shares of Omega Therapeutics subject to Rule 16b-3
Karande Mahesh over six months ago via Macroaxis 
Exercise or conversion by Karande Mahesh of 11300 shares of Omega Therapeutics subject to Rule 16b-3
Moore Yan over six months ago via Macroaxis 
Acquisition by Moore Yan of 477715 shares of Omega Therapeutics subject to Rule 16b-3
Flagship Pioneering Inc over a year ago via Macroaxis 
Omega Therapeutics exotic insider transaction detected
Flagship Pioneering Inc over a year ago via Macroaxis 
Conversion by Flagship Pioneering Inc of 1666666 shares of Omega Therapeutics
Sawhney Roger over a year ago via Macroaxis 
Purchase by Sawhney Roger of 2941 shares of Omega Therapeutics
Afeyan Noubar over a year ago via Macroaxis 
Acquisition by Afeyan Noubar of 19852 shares of Omega Therapeutics subject to Rule 16b-3

Omega Therapeutics Technical and Predictive Indicators

Omega Therapeutics Forecast Models

Omega Therapeutics time-series forecasting models is one of many Omega Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Omega Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Omega Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Omega Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Omega shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Omega Therapeutics. By using and applying Omega Stock analysis, traders can create a robust methodology for identifying Omega entry and exit points for their positions.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Omega Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Omega Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Earnings Calls Now


Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module
Please check Your Equity Center. Note that the Omega Therapeutics information on this page should be used as a complementary analysis to other Omega Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Directory module to find actively traded corporate debentures issued by US companies.

Complementary Tools for Omega Stock analysis

When running Omega Therapeutics price analysis, check to measure Omega Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omega Therapeutics is operating at the current time. Most of Omega Therapeutics' value examination focuses on studying past and present price action to predict the probability of Omega Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Omega Therapeutics' price. Additionally, you may evaluate how the addition of Omega Therapeutics to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Omega Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omega Therapeutics. If investors know Omega will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omega Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
335.9 M
Return On Assets
Return On Equity
The market value of Omega Therapeutics is measured differently than its book value, which is the value of Omega that is recorded on the company's balance sheet. Investors also form their own opinion of Omega Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Omega Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omega Therapeutics' market value can be influenced by many factors that don't directly affect Omega Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omega Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Omega Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omega Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.